-
公开(公告)号:US20230138150A1
公开(公告)日:2023-05-04
申请号:US17991292
申请日:2022-11-21
IPC分类号: C07F9/24 , A61P39/00 , A61K45/06 , C07D241/04 , C07D243/08 , C07D243/10 , C07D401/04 , C07D487/04 , C07F9/6574
摘要: The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol. The compounds of this disclosure also relate to formula I: The use of these compounds as radio- and chemo-protectors is also described.
-
2.
公开(公告)号:US20230099139A1
公开(公告)日:2023-03-30
申请号:US18059765
申请日:2022-11-29
IPC分类号: C07D243/08 , A61K9/127 , C07C229/30 , C07D211/14 , C07D233/02 , C07D241/04
摘要: The present embodiment provides a compound represented by the formula (1): Q-CHR2 (1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.
-
3.
公开(公告)号:US20230071228A1
公开(公告)日:2023-03-09
申请号:US17291937
申请日:2019-11-07
申请人: Translate Bio, Inc.
发明人: Yi Zhang , Frank DeRosa , Shrirang Karve , Michael Heartlein , Saswata Karmakar , Ryan Landis
IPC分类号: C07D241/04 , A61K47/24 , A61K31/7105 , A61K9/127
摘要: The present invention provides, in part, cyclic amino acid lipid compounds of formula (A′), and sub-formulas thereof or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
-
公开(公告)号:US11560358B2
公开(公告)日:2023-01-24
申请号:US17046120
申请日:2019-04-09
申请人: LETAVIS AB
发明人: Mihaela Maria Pop , Paula Vasilichia Bulieris , Ingemar Pongratz , Victor Fruth-Oprisan , Raul-Augustin Mitran
IPC分类号: C07D241/04 , C07C29/78 , C07C49/255
摘要: The present document is directed to co-crystals of resveratrol and/or curcumin with piperazine and their use in medicine and/or as food and feed supplements.
-
公开(公告)号:US11548857B2
公开(公告)日:2023-01-10
申请号:US16812625
申请日:2020-03-09
IPC分类号: C07D243/08 , C07C229/30 , C07D233/02 , C07D241/04 , C07D211/14 , A61K9/127 , A61K31/7088
摘要: The present embodiment provides a compound represented by the formula (1): Q-CHR2 (1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.
-
公开(公告)号:US11530182B2
公开(公告)日:2022-12-20
申请号:US17138346
申请日:2020-12-30
IPC分类号: C07D211/60 , C07D401/06 , C07D401/12 , C07C237/22 , C07C251/24 , C07C255/57 , C07D211/34 , C07D211/96 , C07D233/92 , C07D241/04 , C07D401/10 , C07D403/06 , C07D405/06 , C07D405/12 , A61K45/06
摘要: Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and stemness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit sternness. Disclosed are compounds that affect the Yap1:Oct4 interaction.
-
公开(公告)号:US20220380298A1
公开(公告)日:2022-12-01
申请号:US17575027
申请日:2022-01-13
申请人: The Regents of the University of California , The United States Government represented by the Department of Veteran Affairs
IPC分类号: C07C225/16 , A61P35/00 , C07C33/48 , C07C49/223 , C07C235/34 , C07C235/78 , C07C321/20 , C07D207/08 , C07D211/32 , C07D241/04 , C07D265/30 , C07D303/32 , C07D303/40 , C07D307/52 , C07D333/24
摘要: The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
-
公开(公告)号:US20220356153A1
公开(公告)日:2022-11-10
申请号:US17537110
申请日:2021-11-29
IPC分类号: C07D205/04 , C07D207/08 , C07D207/16 , C07D211/22 , C07D211/46 , C07D211/48 , C07D241/04 , C07D241/08 , C07D265/30 , C07D401/04 , C07D403/06 , C07D403/14 , C07D405/04 , C07D405/12 , C07D413/14 , C07D491/107
摘要: The present disclosure relates to novel compounds, pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurodegerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed.
-
公开(公告)号:US11485714B2
公开(公告)日:2022-11-01
申请号:US17347720
申请日:2021-06-15
发明人: Brijesh Rathi , Prakasha Kempaiah , Agam P. Singh , Snigdha Singh , Yash Gupta , Neha Sharma , Poonam , Ravi Durvsula
IPC分类号: C07D295/125 , A61P33/02 , C07D241/04
摘要: Disclosed herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, related pharmaceutical compositions, and methods for using the same to treat parasitic diseases.
-
公开(公告)号:US11478438B2
公开(公告)日:2022-10-25
申请号:US16787052
申请日:2020-02-11
发明人: Zhiyuan Zhang , Xiaodong Wang , Yaning Su , Hanying Ruan , Yan Ren
IPC分类号: A61K31/165 , A61K31/10 , A61K31/167 , C07C233/01 , C07C235/38 , C07D231/02 , C07D263/04 , C07D205/04 , C07D265/30 , C07D207/12 , C07D211/70 , C07D231/04 , C07D231/08 , C07D233/38 , C07D405/04 , C07D409/04 , C07D241/04 , C07D417/04 , C07D261/02 , C07D263/22 , C07D203/18 , C07D205/08 , C07D207/06 , C07D207/08 , C07D207/20 , C07D207/24 , C07D207/27 , C07D207/333 , C07D211/16 , C07D211/82 , G01C19/5649 , G01C19/5747
摘要: The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
-
-
-
-
-
-
-
-
-